Market Research Logo

Global Hemophilia A Market 2015-2019

About hemophilia A

Hemophilia is a rare bleeding disorder caused by deficiency of clotting factors such as VIII and IX. It is an X-linked recessive disorder, which is more prevalent in males than in females. It is estimated that it affects around 400,000 people per year. The two major types of hemophilia are A and B. Hemophilia A, also called as classical hemophilia or factor VIII deficiency hemophilia, is caused by deficiency of clotting factor VIII. It is transmitted genetically from parent to child during birth. Recombinant clotting factors or plasma-derived clotting factors are being developed for the treatment of this disorder.

Technavio's analysts forecast the global hemophilia A drugs market to grow at a CAGR of 6.25% over the period 2014-2019.

Covered in this report

The report covers the current scenario and the growth prospects of the global hemophilia A drugs market for the period of 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment and prevention of hemophilia A. In this report, the market is also segmented based on the type of therapy.

Technavio's report, Global Hemophilia A Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers APAC, Europe, and Americas; it also covers the landscape of the global hemophilia A drugs market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key regions

  • Americas
  • APAC
  • Europe
Key vendors
  • Baxter International
  • Bayer's
  • CSL Behring
  • Novo Nordisk
  • Pfizer
Other prominent vendors
  • Alnylam Pharmaceuticals
  • Amarna Therapeutics
  • Asklepios
  • Biogen Idec
  • Catalyst Biosciences
  • Dimension Therapeutics
  • Dong-A Socio
  • Emergent BioSolutions
  • Grifols
  • Inspiration Biopharmaceuticals
  • Kedrion Biopharma
  • Octapharma
  • OPKO Health
  • rEVO Biologics
  • Sangamo BioSciences
  • Spark Therapeutics
  • UniQure
Market driver
  • Development of drugs with prolonged action
  • For a full, detailed list, view our report
Market challenge
  • High cost of therapy
  • For a full, detailed list, view our report
Market trend
  • Advances in technology
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Hemophilia A Market 2015-2019

Technavio recognizes the following companies as the key players in the Global Hemophilia A Market: Baxter International, Bayer's, CSL Behring, Novo Nordisk and Pfizer

Other Prominent Vendors in the market are: Alnylam Pharmaceuticals, Amarna Therapeutics, Asklepios, Biogen Idec, Catalyst Biosciences, Dimension Therapeutics, Dong-A Socio, Emergent BioSolutions, Grifols, Inspiration Biopharmaceuticals, Kedrion Biopharma, Octapharma, OPKO Health, rEVO Biologics, Sangamo BioSciences, Spark Therapeutics and UniQure

Commenting on the report, an analyst from Technavio’s team said: “There are new technological advancements in terms of drug manufacturing, development, and delivery. These advances has led to the development of recombinant products. For instance, animal or human plasma proteins are not used to manufacture NovoSeven, thereby decreasing the risk of infection. The use of Fc-fusion technology has increased the half-life of Eloctate in blood, thereby improving drug action.”

According to the report, the development of new hemophilia A therapeutics with prolonged action is prompting market growth. Vendors are developing a number of products, which are in the pipeline stage. The anticipated approval of these products will impact the growth of the market during the forecast period.

Further, the report states that the high cost of treatment leads to the discontinuation of therapy, thereby hampering market growth.

Companies Mentioned

Baxter International, Bayer's, CSL Behring, Novo Nordisk, Pfizer, Alnylam Pharmaceuticals, Amarna Therapeutics, Asklepios, Biogen Idec, Catalyst Biosciences, Dimension Therapeutics, Dong-A Socio, Emergent BioSolutions, Grifols, Inspiration Biopharmaceuticals, Kedrion Biopharma, Octapharma, OPKO Health, rEVO Biologics, Sangamo BioSciences, Spark Therapeutics, UniQure

  • Executive summary
    • Highlights
  • Scope of the report
    • Market overview
    • Top-vendor offerings
      • Table Product offerings
  • Market research methodology
    • Research methodology
    • Economic indicators
  • Introduction
    • Key market highlights
  • Disease overview
    • Understanding the disease
    • Risk factors
    • Signs and symptoms
    • Diagnosis
    • Treatment
    • Epidemiology
      • Table Number of prevalence cases of hemophilia A in five countries 2011
  • Pipeline portfolio
    • Table Key late-stage drugs under development for hemophilia A
    • Key information on pipeline candidates
  • Market landscape
    • Market overview
    • Market size and forecast
      • Table Global hemophilia A drugs market 2014-2019 ($ billions)
    • Five forces analysis
      • Table Five forces analysis
  • Segmentation by type of therapy
    • Table Global hemophilia A drugs market by type of therapy
    • Plasma-derived therapies
    • Recombinant therapies
      • Table Segmentation by type of therapy for hemophilia A
  • Segmentation by disease management
    • Table Global hemophilia A drugs market by disease management
    • On-demand therapy
    • Prophylaxis
      • Table Types of prophylaxis
    • Inhibitors
      • Table Segmentation by disease management of hemophilia A
  • Geographical segmentation
    • Table Segmentation of global hemophilia A drugs market by geography in 2014
  • Market drivers
  • Impact of drivers
    • Table Impact of drivers
  • Market challenges
  • Impact of drivers and challenges
    • Table Impact of drivers and challenges
  • Market trends
  • Vendor landscape
    • Competitive scenario
    • Market share analysis 2014
      • Table Baxter: Global YoY growth and revenue of hemophilia products 2012-2014 ($ millions)
      • Table Baxter: Key takeaways
      • Table Novo Nordisk: Global YoY growth and revenue of hemophilia products 2012-2014 ($ millions)
      • Table Novo Nordisk: Key takeaways
      • Table Bayer: Global YoY growth and revenue of Kogenate FS 2012-2014 ($ millions)
      • Table Bayer's: Key takeaways
      • Table Pfizer: Global YoY growth and revenue of Xyntha/ReFactoAF 2012-2014 ($ millions)
      • Table Pfizer: Key takeaways
      • Table CSL Behring: Global YoY growth and revenue of hemophilia products 2013-2014 ($ millions)
      • Table CSL Behring: Key takeaways
    • Other prominent vendors
  • Key vendor analysis
    • Baxter
    • Bayer HealthCare
    • CSL Behring
      • Table CSL Behring: Product segmentation by revenue 2014
      • Table CSL Behring: Geographical segmentation by revenue 2014
      • Table Novo Nordisk: Business segmentation by revenue 2014
      • Table Novo Nordisk: Business segmentation by revenue 2013 and 2014
      • Table Novo Nordisk: Geographical segmentation by revenue 2014
      • Table Novo Nordisk: R&D expenditure 2014
    • Pfizer
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report